The effector site of leishmania pyruvate kinase as a
chemotherapeutic target
Linda A Fothergill-Gilmore1, Véronique Hannaert2 &
Paul A M Michels2, (1) ICMB, University of Edinburgh, Edinburgh EH9 3JR,
Scotland, and (2) Christian de Duve Institute of Cellular Pathology, Université
Catholique de Louvain, B-1200 Brussels, Belgium.
Glycolytic enzymes have been identified as promising targets
for new drugs against trypanosomatids because these enzymes play an essential
role in ATP supply. The effector site of parasite pyruvate kinase (PYK)
displays important differences from human PYKs, and thus offers opportunities
for the development of parasite-specific inhibitors. Among the differences
is the presence of two basic residues (Lys453 and His480) that are unique
to trypanosomatid PYKs. The crystal structure of leishmania PYK has been
solved in the inactive T-state in which the effector site has no bound ligand.
However, it can be inferred by comparative modelling that Lys453 and His480
define the effector specificity of the parasite enzyme. The allosteric
activator is fructose bisphosphate that has a phospho group in the 2-position
instead of the 1-position as for PYKs from all other species, including humans.
We have verified the putative binding role of Lys453 and
His480 by making a series of site-directed mutants. All mutants show
complete loss of the capability to respond to activation by fructose 2,6-bisphosphate,
thus confirming our prediction. In addition, we have prepared two mutants
for use as tools to screen the large number of compounds we anticipate from
ligand docking, database mining and combinatorial chemistry. Wild-type
trypanosomatid PYK has no tryptophan residues, and we have introduced this
residue into two different positions near the effector site (F442W and E451W).
Both mutants show fluorescence quenching in response to substrates and effectors,
and will thus play an important role in screening combinatorial libraries.
This work was supported by the European Commission through its INCO-DC programme.
|
|